Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$26.17
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.63%
Accommodative
10-Year Treasury
4.48%
2026-05-01
Unemployment
4.3%
Near full employment
CPI Index
332.4
2026-04-01
M2 Money Supply
$22.8T
2026-04-01
The Federal Funds rate stands at 3.63% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.48%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.3%; Industrial production index is at 102.5; M2 money supply is $22.8T; CPI index stands at 332.4.
SWOT Analysis — PFE
Inflationary BoomStrengths
No standout strengths identified from the filing.
Weaknesses
Operating Cash Flow: $11.7B (-8.2% YoY) — Operating cash flow fell 8% but remained positive.
EPS (Diluted): $1.36 (-3.5% YoY) — Earnings per share fell 4%.
Net Income: $7.8B (-3.2% YoY) — Profit fell 3% but remained positive.
Total Assets: $208.2B (-2.5% YoY) — Total assets shrank 2% — the balance sheet contracted.
Revenue: $62.6B (-1.6% YoY) — Revenue fell 2% — the company generated less from its core operations.
Opportunities
No clear opportunities identified at this time.
Threats
Current ratio of 1.16x — thin liquidity buffer against short-term obligations.
Financial Charts
Revenue vs Net Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
Operating Cash Flow
$11.7B
was $12.7B
Operating cash flow fell 8% but remained positive.
EPS (Diluted)
$1.36
was $1.41
Earnings per share fell 4%.
Net Income
$7.8B
was $8.0B
Profit fell 3% but remained positive.
Total Assets
$208.2B
was $213.4B
Total assets shrank 2% — the balance sheet contracted.
Revenue
$62.6B
was $63.6B
Revenue fell 2% — the company generated less from its core operations.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Current ratio of 1.16x — thin liquidity buffer against short-term obligations.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade PFE
Links open broker research pages. Not an endorsement or recommendation.
Research Pfizer Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.